Development of Acute Tolerance to Bumetanide: Bolus Injection Studies
dc.contributor.author | Cook, Jack A. | en_US |
dc.date.accessioned | 2006-09-08T19:20:32Z | |
dc.date.available | 2006-09-08T19:20:32Z | |
dc.date.issued | 1987-10 | en_US |
dc.identifier.citation | Cook, Jack A.; (1987). "Development of Acute Tolerance to Bumetanide: Bolus Injection Studies." Pharmaceutical Research 4(5): 379-384. <http://hdl.handle.net/2027.42/41515> | en_US |
dc.identifier.issn | 1573-904X | en_US |
dc.identifier.issn | 0724-8741 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/41515 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3508546&dopt=citation | en_US |
dc.description.abstract | Bumetanide was administered intravenously to four mongrel dogs, in a random crossover fashion, at doses of 0.05 mg/kg (I), 0.15 mg/kg (II), and 0.5 mg/kg (III) where urinary losses were replaced with lactated Ringer's solution at 1.5 ml/min (hydropenic conditions) or at a dose of 0.5 mg/kg (IV) where urinary losses were replaced with lactated Ringer's solution isovolumetrically (euvolemic conditions). Serial plasma and urine samples were assayed for bumetanide by high-performance liquid chromatography (HPLC) and for sodium by flame photometry. There were no significant differences in the pharmacokinetic parameters of bumetanide among Treatments I–IV. The dynamic parameters E max (maximum effect attributable to the drug) and s (slope factor) were not different between treatments. However, a consistent, demonstrable increase in ER 50 (urinary excretion rate of drug producing 50% of E max ) was observed among Treatments I (2.34 µg/min), II (3.92 µg/min), and III (6.54 µg/min); also, a significant decrease in ER 50 was observed between Treatment III (6.54 µg/min) and Treatment IV (2.66 µg/min). These results show that hydration status has a marked effect on natriuretic and diuretic response and that tolerance can rapidly develop within a single intravenous dose of bumetanide. | en_US |
dc.format.extent | 951635 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Media | en_US |
dc.subject.other | Dynamics | en_US |
dc.subject.other | Bumetanide | en_US |
dc.subject.other | Biochemistry, General | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Pharmacy | en_US |
dc.subject.other | Medical Law | en_US |
dc.subject.other | Kinetics | en_US |
dc.subject.other | Biomedical Engineering | en_US |
dc.subject.other | Acute Tolerance | en_US |
dc.title | Development of Acute Tolerance to Bumetanide: Bolus Injection Studies | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | College of Pharmacy, The University of Michigan, Ann Arbor, Michigan, 48109-1065 | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 3508546 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/41515/1/11095_2004_Article_306385.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1023/A:1016426110571 | en_US |
dc.identifier.source | Pharmaceutical Research | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.